The FY19 Defense Appropriation provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP)to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
FY19 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.
The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Applications submitted to the FY19 PCRP must address one or more of the program’s Overarching Challenges:
· Improve the quality of life for survivors of prostate cancer
· Develop treatments that improve outcomes for men with lethal prostate cancer
· Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
· Define the biology of lethal prostate cancer to reduce death
https://cdmrp.army.mil/funding/pcrp
Health Disparity Research Award– Letter of Intent due June 27, 2019
Established Investigators: Independent investigators at all levels
or
New Investigators: Investigators that meet the following criteria at the application submission deadline date:
· Have the freedom to pursue individual aims without formal mentorship
· Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award
· Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)
· Supports ideas that have the high potential to make a significant impact in reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality.
· Primary emphasis will be placed on the potential impact of the proposed work.
· Preliminary data are encouraged, but not required.
· Proposed projects may include basic, translational, population science, or clinical research, including clinical trials.
· Must address at least one of the FY19 PCRP Overarching Challenges
· New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
· Established Investigators:
· Maximum funding of $750,000 for direct costs (plus indirect costs).
· New Investigators:
· Maximum funding of $600,000 for direct costs (plus indirect costs).
· Maximum period of performance is 3 years.
Translational Science Award – Letter of Intent due June 27, 2019
· Independent investigators at all levels
· Supports translational studies that will advance promising ideas into clinical applications.
· The potential impact of the research is expected to be significant and go beyond an incremental advance.
· Preliminary data to support feasibility are required.
· Proposed projects may include basic, translational, population science or clinical research, but must demonstrate clinical relevance. Clinical trials are not allowed.
· Maximum funding of $750,000 for direct costs (plus indirect costs).
· Maximum period of performance is 3 years.
Clinical Trial Award – Letter of Intent due June 27, 2019
· Independent investigators at all levels
· Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions that will have a major impact on one or more of the FY19 PCRP Overarching Challenges.
· Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types.
· Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place by the time of application submission.
· Letter of support to demonstrate proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).
· Clinical trials are expected to be initiated within 12 months of the award date.
· Maximum funding of $2,000,000 for direct costs (plus indirect costs).
· Maximum period of performance is 4 years.
Synergistic Population and Data Science Award – Letter of Intent is due June 27, 2019
· Independent investigators with a faculty-level appointment (or equivalent)
· Supports multi-institutional partnerships that will leverage existing prostate cancer patient databases and/or cohorts to address high-impact questions responsive to the FY19 PCRP Overarching Challenges.
· Allows for development of infrastructure to facilitate access to multiple databases/cohorts, as well as conducting hypothesis-based studies utilizing the multi-institutional datasets.
· Minimum of three institutions and three patient databases and/or cohorts is required.
· Maximum funding of $1,500,000 for direct costs (plus indirect costs).
· Maximum period of performance is 4 years.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk
301-682-5507
help@eBrap.org
